An Expanded Access Program for AM0010 (Pegilodecakin)
NCT03554434 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-03-02
Summary
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
Conditions
- Melanoma
- Prostate Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Pancreatic Carcinoma
- Non-small Cell Lung Carcinoma
- Solid Tumors
- Breast Cancer
Interventions
- BIOLOGICAL
-
AM0010
AM0010
Sponsors & Collaborators
-
ARMO BioSciences
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Contact Lilly at 1-800-LillyRx (1-800-545-5979) · Eli Lilly and Company
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
NCT03597282 ·Status: TERMINATED ·Phase: PHASE1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
NCT01720836 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immunotherapy of Stage III/IV Melanoma Patients
NCT00112242 ·Status: COMPLETED ·Phase: PHASE1
-
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04616248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
NCT00704938 ·Status: TERMINATED ·Phase: PHASE2
-
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT05269381 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Non-Viral TCR Gene Therapy
NCT04102436 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT01633970 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
NCT02432963 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer
NCT01069640 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
NCT02350673 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
NCT00019084 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
NCT00553618 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
NCT03012620 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT03428802 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
NCT02498912 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
NCT03568058 ·Status: COMPLETED ·Phase: PHASE1
-
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00091338 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
NCT02737475 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
NCT06963697 ·Status: AVAILABLE
-
Vaccination Plus Ontak in Patients With Metastatic Melanoma
NCT00515528 ·Status: TERMINATED ·Phase: PHASE2
-
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
NCT02678741 ·Status: COMPLETED ·Phase: PHASE1/PHASE2